法国冠状动脉门诊2型糖尿病患者使用Icosapent Ethyl的资格

IF 3 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Archives of Medical Science Pub Date : 2023-10-08 DOI:10.5114/aoms/173511

Pierre François Sabouret, Jean-Claude Dib, Fiona Ecarnot, Maciej Banach, Nicolas Lellouche

{"title":"法国冠状动脉门诊2型糖尿病患者使用Icosapent Ethyl的资格","authors":"Pierre François Sabouret, Jean-Claude Dib, Fiona Ecarnot, Maciej Banach, Nicolas Lellouche","doi":"10.5114/aoms/173511","DOIUrl":null,"url":null,"abstract":"Introduction We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD). Material and methods Prospective patients with type 2 diabetes and CAD were included from 03/2019 to 12/2020. Results 574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean LDL-cholesterol was 85 mg/dL, mean HbA1c 7.1%, mean triglycerides 148 mg/dL; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA. Conclusions In this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"66 1","pages":"0"},"PeriodicalIF":3.0000,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Eligibility for Icosapent Ethyl in a French Population of Coronary Outpatients With Type 2 Diabetes\",\"authors\":\"Pierre François Sabouret, Jean-Claude Dib, Fiona Ecarnot, Maciej Banach, Nicolas Lellouche\",\"doi\":\"10.5114/aoms/173511\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD). Material and methods Prospective patients with type 2 diabetes and CAD were included from 03/2019 to 12/2020. Results 574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean LDL-cholesterol was 85 mg/dL, mean HbA1c 7.1%, mean triglycerides 148 mg/dL; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA. Conclusions In this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.\",\"PeriodicalId\":8278,\"journal\":{\"name\":\"Archives of Medical Science\",\"volume\":\"66 1\",\"pages\":\"0\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Medical Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/aoms/173511\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/aoms/173511","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

我们确定了在冠状动脉疾病(CAD)中使用二十戊二烯(EPA)治疗的资格。材料与方法2019年3月至2020年12月纳入前瞻性2型糖尿病合并CAD患者。结果纳入574例患者;平均年龄71岁，81%为男性，其他危险因素患病率高(81%为高血压)。平均ldl -胆固醇为85 mg/dL，平均HbA1c为7.1%，平均甘油三酯为148 mg/dL;82%接受了他汀类药物治疗。根据国家脂质协会的标准，31%的人有资格获得EPA。在这项对日常实践中连续的、未选择的CAD患者的当代调查中，几乎三分之一的患者可能符合EPA的条件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Eligibility for Icosapent Ethyl in a French Population of Coronary Outpatients With Type 2 Diabetes

Introduction We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD). Material and methods Prospective patients with type 2 diabetes and CAD were included from 03/2019 to 12/2020. Results 574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean LDL-cholesterol was 85 mg/dL, mean HbA1c 7.1%, mean triglycerides 148 mg/dL; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA. Conclusions In this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Archives of Medical Science 医学-医学：内科

CiteScore

4.90

自引率

7.90%

发文量

139

审稿时长

1.7 months

期刊介绍： Archives of Medical Science (AMS) publishes high quality original articles and reviews of recognized scientists that deal with all scientific medicine. AMS opens the possibilities for young, capable scientists. The journal would like to give them a chance to have a publication following matter-of-fact, professional review by outstanding, famous medical scientists. Thanks to that they will have an opportunity to present their study results and/or receive useful advice about the mistakes they have made so far. The second equally important aim is a presentation of review manuscripts of recognized scientists about the educational capacity, in order that young scientists, often at the beginning of their scientific carrier, could constantly deepen their medical knowledge and be up-to-date with current guidelines and trends in world-wide medicine. The fact that our educational articles are written by world-famous scientists determines their innovation and the highest quality.